Autonomic dysfunction: A unifying multiple sclerosis theory, linking chronic cerebrospinal venous insufficiency, vitamin D3, and Epstein-Barr virus

Autoimmunity Reviews

Volumn 12, Issue 2, 2012, Pages 250-259

  Sternberg, Zohara ^a  

^a JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Blood pressure; Cardiovascular system; Cerebrovascular circulation; Hemodynamic; Infectious mononucleosis; Transcranial Doppler; Vitamin D deficiency

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CALCITRIOL; FERRITIN; HLA DQ ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; NITRIC OXIDE;

APOPTOSIS; AUTONOMIC DYSFUNCTION; AUTOREGULATION; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN PERFUSION; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRAL VENOUS PRESSURE; CHRONIC CEREBROSPINAL VENOUS INSUFFICIENCY; CROHN DISEASE; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; INTRACRANIAL PRESSURE; MEAN ARTERIAL PRESSURE; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERFUSION PRESSURE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VASOCONSTRICTION;

AUTONOMIC NERVOUS SYSTEM DISEASES; CEREBRAL VEINS; CHOLECALCIFEROL; HERPESVIRUS 4, HUMAN; HUMANS; MULTIPLE SCLEROSIS; SPINAL CORD; VENOUS INSUFFICIENCY;

EID: 84870243957     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.04.004     Document Type: Review

References (185)

1. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
2. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846.
3. Charil A., Filippi M. Inflammatory demyelination and neurodegeneration in early multiple sclerosis. J Neurol Sci 2007, 259:7-15.
4. De Stefano N., Narayanan S., Francis G.S., Arnaoutelis R., Tartaglia M.C., Antel J.P., et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001, 58:65-70.
5. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747.
6. Gunnarsson M., Malmestrom C., Axelsson M., Sundstrom P., Dahle C., Vrethem M., et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011, 69:83-89.
7. Mendes A., Sa M.J. Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works. Arq Neuropsiquiatr 2011, 69:536-543.
8. Panitch H., Miller A., Paty D., Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004, 63:1788-1795.
9. Hillert J., Olerup O. HLA and MS. Neurology 1993, 43:2426-2427.
10. Haines J.L., Terwedow H.A., Burgess K., Pericak-Vance M.A., Rimmler J.B., Martin E.R., et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum Mol Genet 1998, 7:1229-1234.
11. Chiang Y.J., Kole H.K., Brown K., Naramura M., Fukuhara S., Hu R.J., et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 2000, 403:216-220.
12. Tuohy V.K., Yu M., Yin L., Kawczak J.A., Kinkel P.R. Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J Autoimmun 1999, 13:11-20.
13. Willer C.J., Dyment D.A., Risch N.J., Sadovnick A.D., Ebers G.C. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 2003, 100:12877-12882.
14. Burrell A.M., Handel A.E., Ramagopalan S.V., Ebers G.C., Morahan J.M. Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC). Discov Med 2011, 11:187-196.
15. Kurtzke J.F., Heltberg A. Multiple sclerosis in the Faroe Islands: an epitome. J Clin Epidemiol 2001, 54:1-22.
16. Reiber H., Ungefehr S., Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998, 4:111-117.
17. Lycke J., Svennerholm B., Hjelmquist E., Frisen L., Badr G., Andersson M., et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol 1996, 243:214-224.
18. Bech E., Lycke J., Gadeberg P., Hansen H.J., Malmestrom C., Andersen O., et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 2002, 58:31-36.
19. Friedman J.E., Zabriskie J.B., Plank C., Ablashi D., Whitman J., Shahan B., et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler 2005, 11:286-295.
20. Wucherpfennig K.W., Strominger J.L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995, 80:695-705.
21. Thacker E.L., Mirzaei F., Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006, 59:499-503.
22. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007, 61:504-513.
23. Pohl D., Krone B., Rostasy K., Kahler E., Brunner E., Lehnert M., et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006, 67:2063-2065.
24. Ascherio A., Munger K.L., Lennette E.T., Spiegelman D., Hernan M.A., Olek M.J., et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001, 286:3083-3088.
25. Sundstrom P., Juto P., Wadell G., Hallmans G., Svenningsson A., Nystrom L., et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004, 62:2277-2282.
26. Wandinger K., Jabs W., Siekhaus A., Bubel S., Trillenberg P., Wagner H., et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000, 55:178-184.
27. Bray P.F., Luka J., Culp K.W., Schlight J.P. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 1992, 42:1798-1804.
28. Lang H.L., Jacobsen H., Ikemizu S., Andersson C., Harlos K., Madsen L., et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002, 3:940-943.
29. Prat E., Tomaru U., Sabater L., Park D.M., Granger R., Kruse N., et al. HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J Neuroimmunol 2005, 167:108-119.
30. Perl A. Role of endogenous retroviruses in autoimmune diseases. Rheum Dis Clin North Am 2003, 29:123-143. vii.
31. Rickinson A.B., KE Epstein-Barr virus. Fields virology 2001, 2575-2627. D.M. Knipe, P.M. Howley (Eds.).
32. Pender M.P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003, 24:584-588.
33. Colombo M., Dono M., Gazzola P., Roncella S., Valetto A., Chiorazzi N., et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 2000, 164:2782-2789.
34. Owens G.P., Ritchie A.M., Burgoon M.P., Williamson R.A., Corboy J.R., Gilden D.H. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol 2003, 171:2725-2733.
35. Serafini B., Rosicarelli B., Franciotta D., Magliozzi R., Reynolds R., Cinque P., et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007, 204:2899-2912.
36. Horley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001, 1:75-82.
37. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003, 3:801-812.
38. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
39. Dreyfus D.H. Autoimmune disease: a role for new anti-viral therapies?. Autoimmun Rev 2011, 11:88-97.
40. Kurtzke J.F. Geography in multiple sclerosis. J Neurol 1977, 215:1-26.
41. van der Mei I.A., Ponsonby A.L., Dwyer T., Blizzard L., Simmons R., Taylor B.V., et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003, 327:316.
42. Islam T., Gauderman W.J., Cozen W., Mack T.M. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007, 69:381-388.
43. Yetley E.A. Assessing the vitamin D status of the US population. Am J Clin Nutr 2008, 88:558S-564S.
44. Holick M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004, 80:1678S-1688S.
45. Westberg M., Feychting M., Jonsson F., Nise G., Gustavsson P. Occupational exposure to UV light and mortality from multiple sclerosis. Am J Ind Med 2009, 52:353-357.
46. Willer C.J., Dyment D.A., Sadovnick A.D., Rothwell P.M., Murray T.J., Ebers G.C. Timing of birth and risk of multiple sclerosis: population based study. BMJ 2005, 330:120.
47. Soilu-Hanninen M., Laaksonen M., Laitinen I., Eralinna J.P., Lilius E.M., Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008, 79:152-157.
48. Ramagopalan S.V., Maugeri N.J., Handunnetthi L., Lincoln M.R., Orton S.M., Dyment D.A., et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009, 5:e1000369.
49. Handunnetthi L., Ramagopalan S.V., Ebers G.C. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology 2010, 74:1905-1910.
50. Ahn J., Yu K., Stolzenberg-Solomon R., Simon K.C., McCullough M.L., Gallicchio L., et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010, 19:2739-2745.
51. Cantorna M.T., Zhu Y., Froicu M., Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004, 80:1717S-1720S.
52. Sabetta J.R., DePetrillo P., Cipriani R.J., Smardin J., Burns L.A., Landry M.L. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS One 2010, 5:e11088.
53. Roth D.E., Shah R., Black R.E., Baqui A.H. Vitamin D status and acute lower respiratory infection in early childhood in Sylhet, Bangladesh. Acta Paediatr 2010, 99:389-393.
54. Grant W.B. Hypothesis - ultraviolet-B irradiance and vitamin D reduce the risk of viral infections and thus their sequelae, including autoimmune diseases and some cancers. Photochem Photobiol 2008, 84:356-365.
55. Grant W.B. Latitude and multiple sclerosis prevalence: vitamin D reduces risk of Epstein-Barr virus infection. Mult Scler 2010, 16:373. author reply 4-5.
56. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol 2009, 256:1468-1479.
57. Zamboni P., Galeotti R., Menegatti E., Malagoni A.M., Tacconi G., Dall'Ara S., et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80:392-399.
58. Zamboni P. The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med 2006, 99:589-593.
59. Kilic T., Akakin A. Anatomy of cerebral veins and sinuses. Front Neurol Neurosci 2008, 23:4-15.
60. Zamboni P., Consorti G., Galeotti R., Gianesini S., Menegatti E., Tacconi G., et al. Venous collateral circulation of the extracranial cerebrospinal outflow routes. Curr Neurovasc Res 2009, 6:204-212.
61. Law M., Saindane A.M., Ge Y., Babb J.S., Johnson G., Mannon L.J., et al. Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology 2004, 231:645-652.
62. Franceschi C. The unsolved puzzle of multiple sclerosis and venous function. J Neurol Neurosurg Psychiatry 2009, 80:358.
63. Zamboni P., Menegatti E., Galeotti R., Malagoni A.M., Tacconi G., Dall'Ara S., et al. The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis. J Neurol Sci 2009, 282:21-27.
64. Bartolomei I., Salvi F., Galeotti R., Salviato E., Alcanterini M., Menegatti E., et al. Hemodynamic patterns of chronic cerebrospinal venous insufficiency in multiple sclerosis. Correlation with symptoms at onset and clinical course. Int Angiol 2010, 29:183-188.
65. Al-Omari M.H., Rousan L.A. Internal jugular vein morphology and hemodynamics in patients with multiple sclerosis. Int Angiol 2010, 29:115-120.
66. Zivadinov R., Marr K., Cutter G., Ramanathan M., Benedict R.H., Kennedy C., et al. Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology 2011, 77:138-144.
67. Doepp F., Wurfel J.T., Pfueller C.F., Valdueza J.M., Petersen D., Paul F., et al. Venous drainage in multiple sclerosis: a combined MRI and ultrasound study. Neurology 2011, 77:1745-1751.
68. Doepp F., Paul F., Valdueza J.M., Schmierer K., Schreiber S.J. No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol 2010, 68:173-183.
69. Marder E., Gupta P., Greenberg B.M., Frohman E.M., Awad A.M., Bagert B., et al. No cerebral or cervical venous insufficiency in US veterans with multiple sclerosis. Arch Neurol 2011, 68:1521-1525.
70. Centonze D., Floris R., Stefanini M., Rossi S., Fabiano S., Castelli M., et al. Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity. Ann Neurol 2011, 70:51-58.
71. Sundstrom P., Wahlin A., Ambarki K., Birgander R., Eklund A., Malm J. Venous and cerebrospinal fluid flow in multiple sclerosis: a case - control study. Ann Neurol 2010, 68:255-259.
72. Wattjes M.P., van Oosten B.W., de Graaf W.L., Seewann A., Bot J.C., van den Berg R., et al. No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. J Neurol Neurosurg Psychiatry 2011, 82:429-435.
73. Zivadinov R., Lopez-Soriano A., Weinstock-Guttman B., Schirda C.V., Magnano C.R., Dolic K., et al. Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. Radiology 2011, 258:562-570.
74. Zamboni P., Galeotti R., Menegatti E., Malagoni A.M., Gianesini S., Bartolomei I., et al. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg 2009, 50:1348-1358. e1-3.
75. Bagert B.A., Marder E., Stuve O. Chronic cerebrospinal venous insufficiency and multiple sclerosis. Arch Neurol 2011, 68:1379-1384.
76. Lassmann H. Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain Pathol 2005, 15:217-222.
77. Lummel N., Boeckh-Behrens T., Schoepf V., Burke M., Bruckmann H., Linn J. Presence of a central vein within white matter lesions on susceptibility weighted imaging: a specific finding for multiple sclerosis?. Neuroradiology 2011, 53:311-317.
78. Worthington V., Killestein J., Eikelenboom M.J., Teunissen C.E., Barkhof F., Polman C.H., et al. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology 2010, 75:1617-1622.
79. Meyer-Schwickerath R., Haug C., Hacker A., Fink F., Seidel D., Hartung H.P., et al. Intracranial venous pressure is normal in patients with multiple sclerosis. Mult Scler 2011, 17:637-638.
80. Weinstock-Guttman B., Zivadinov R., Cutter G., Tamano-Blanco M., Marr K., Badgett D., et al. Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients. PLoS One 2011, 6:e16802.
81. Joyner M.J., Charkoudian N., Wallin B.G. A sympathetic view of the sympathetic nervous system and human blood pressure regulation. Exp Physiol 2008, 93:715-724.
82. Elenkov I.J., Wilder R.L., Chrousos G.P., Vizi E.S. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000, 52:595-638.
83. Sanders V.M., Straub R.H. Norepinephrine, the beta-adrenergic receptor, and immunity. Brain Behav Immun 2002, 16:290-332.
84. Feigl E.O. Neural control of coronary blood flow. J Vasc Res 1998, 35:85-92.
85. Czura C.J., Tracey K.J. Autonomic neural regulation of immunity. J Intern Med 2005, 257:156-166.
86. Pavlov V.A., Tracey K.J. Neural regulators of innate immune responses and inflammation. Cell Mol Life Sci 2004, 61:2322-2331.
87. Saari A., Tolonen U., Paakko E., Suominen K., Jauhiainen J., Sotaniemi K.A., et al. Sudomotor dysfunction in patients with optic neuritis. Clin Auton Res 2010, 20:199-204.
88. Bradley W.E., Logothetis J.L., Timm G.W. Cystometric and sphincter abnormalities in multiple sclerosis. Neurology 1973, 23:1131-1139.
89. Hinds J.P., Eidelman B.H., Wald A. Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology 1990, 98:1538-1542.
90. Betts C.D., D'Mellow M.T., Fowler C.J. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993, 56:245-250.
91. Sanya E.O., Tutaj M., Brown C.M., Goel N., Neundorfer B., Hilz M.J. Abnormal heart rate and blood pressure responses to baroreflex stimulation in multiple sclerosis patients. Clin Auton Res 2005, 15:213-218.
92. Lorberboym M., Lampl Y., Nikolov G., Sadeh M., Gilad R. I-123 MIBG cardiac scintigraphy and autonomic test evaluation in multiple sclerosis patients. J Neurol 2008, 255:211-216.
93. Labuz-Roszak B., Pierzchala K. Difficulties in the diagnosis of autonomic dysfunction in multiple sclerosis. Clin Auton Res 2007, 17:375-377.
94. Flachenecker P., Reiners K., Krauser M., Wolf A., Toyka K.V. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler 2001, 7:327-334.
95. Flachenecker P., Rufer A., Bihler I., Hippel C., Reiners K., Toyka K.V., et al. Fatigue in MS is related to sympathetic vasomotor dysfunction. Neurology 2003, 61:851-853.
96. Flachenecker P., Wolf A., Krauser M., Hartung H.P., Reiners K. Cardiovascular autonomic dysfunction in multiple sclerosis: correlation with orthostatic intolerance. J Neurol 1999, 246:578-586.
97. McDougall A.J., McLeod J.G. Autonomic nervous system function in multiple sclerosis. J Neurol Sci 2003, 215:79-85.
98. Gunal D.I., Afsar N., Tanridag T., Aktan S. Autonomic dysfunction in multiple sclerosis: correlation with disease-related parameters. Eur Neurol 2002, 48:1-5.
99. Nazliel B., Irkec C., Kocer B. The roles of blink reflex and sympathetic skin response in multiple sclerosis diagnosis. Mult Scler 2002, 8:500-504.
100. Vita G., Fazio M.C., Milone S., Blandino A., Salvi L., Messina C. Cardiovascular autonomic dysfunction in multiple sclerosis is likely related to brainstem lesions. J Neurol Sci 1993, 120:82-86.
101. Kodounis A., Stamboulis E., Constantinidis T.S., Liolios A. Measurement of autonomic dysregulation in multiple sclerosis. Acta Neurol Scand 2005, 112:403-408.
102. Leussink V.I., MM, Toyka K.V., Rieckmann P., P.F Autonomic dysregulation in patients with clinically isolated syndrome. ECTRIMS 2003 Annual Meeting Multiple Sclerosis: Milan, It 2003:S91 2003.
103. Surakka J., Ruutiainen J., Romberg A., Puukka P., Kronholm E., Karanko H. Pupillary function in early multiple sclerosis. Clin Auton Res 2008, 18:150-154.
104. Marrosu F., Maleci A., Cocco E., Puligheddu M., Barberini L., Marrosu M.G. Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. Mult Scler 2007, 13:1200-1202.
105. Khoury S.J., Healy B.C., Kivisakk P., Viglietta V., Egorova S., Guttmann C.R., et al. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol 2010, 67:1055-1061.
106. Rajda C., Bencsik K., Vecsei L.L., Bergquist J. Catecholamine levels in peripheral blood lymphocytes from multiple sclerosis patients. J Neuroimmunol 2002, 124:93-100.
107. Karaszewski J.W., Reder A.T., Anlar B., Kim W.C., Arnason B.G. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28-suppressor cell. Ann Neurol 1991, 30:42-47.
108. Zoukos Y., Leonard J.P., Thomaides T., Thompson A.J., Cuzner M.L. beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. Ann Neurol 1992, 31:657-662.
109. Zoukos Y., Thomaides T.N., Kidd D., Cuzner M.L., Thompson A. Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study. J Neurol Neurosurg Psychiatry 2003, 74:197-202.
110. Zoukos Y., Kidd D., Woodroofe M.N., Kendall B.E., Thompson A.J., Cuzner M.L. Increased expression of high affinity IL-2 receptors and beta-adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis. Brain 1994, 117(Pt 2):307-315.
111. Giorelli M., Livrea P., Trojano M. Post-receptorial mechanisms underlie functional disregulation of beta2-adrenergic receptors in lymphocytes from Multiple Sclerosis patients. J Neuroimmunol 2004, 155:143-149.
112. Zeinstra E., Wilczak N., De Keyser J. [3H]dihydroalprenolol binding to beta adrenergic receptors in multiple sclerosis brain. Neurosci Lett 2000, 289:75-77.
113. Kooi E.J., Prins M., Bajic N., Belien J.A., Gerritsen W.H., van Horssen J., et al. Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathol 2011, 122:313-322.
114. Anlar B., Karaszewski J.W., Reder A.T., Arnason B.G. Increased muscarinic cholinergic receptor density on CD4+ lymphocytes in progressive multiple sclerosis. J Neuroimmunol 1992, 36:171-177.
115. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004, 5:347-360.
116. Reis D.J., Golanov E.V. Autonomic and vasomotor regulation. Int Rev Neurobiol 1997, 41:121-149.
117. Burton A.C. On the physical equilibrium of small blood vessels. Am J Physiol 1951, 164:319-329.
118. Panerai R.B. The critical closing pressure of the cerebral circulation. Med Eng Phys 2003, 25:621-632.
119. 2 reactivity, and intracranial pressure: a mathematical model. Am J Physiol 1998, 274:H1715-H1728.
120. Azevedo E., Castro P., Santos R., Freitas J., Coelho T., Rosengarten B., et al. Autonomic dysfunction affects cerebral neurovascular coupling. Clin Auton Res 2011, 21:395-403.
121. Sternberg Z., Leung C., Sternberg D., Li F., Hojnacki D., Levy E. The prevalence of cardiovascular risk factors in multiple sclerosis patients. Under peer review submission 2012.
122. Hill L. Cerebral blood flow and intracranial pressure. Update in Anaesthesia 2007.
123. Caicedo A., De Smet D., Vanderhaegen J., Naulaers G., Wolf M., Lemmers P., et al. Impaired cerebral autoregulation using near-infrared spectroscopy and its relation to clinical outcomes in premature infants. Adv Exp Med Biol 2011, 701:233-239.
124. Chao A.C., Hu H.H., Liao K.K., Chern C.M. Dynamic cerebrovascular regulation in patients with autonomic dysfunction: a transcranial Doppler study. J Chin Med Assoc 2003, 66:339-345.
125. Nasr N., Czosnyka M., Arevalo F., Hanaire H., Guidolin B., Larrue V. Autonomic neuropathy is associated with impairment of dynamic cerebral autoregulation in type 1 diabetes. Auton Neurosci 2011, 160:59-63.
126. Hollingsworth K.G., Jones D.E., Taylor R., Frith J., Blamire A.M., Newton J.L. Impaired cerebral autoregulation in primary biliary cirrhosis: implications for the pathogenesis of cognitive decline. Liver Int 2010, 30:878-885.
127. Gisolf J., van Lieshout J.J., van Heusden K., Pott F., Stok W.J., Karemaker J.M. Human cerebral venous outflow pathway depends on posture and central venous pressure. J Physiol 2004, 560:317-327.
128. Persson S. Endocrinology of cardiac failure. Pathophysiologic aspects - hemodynamics. Acta Med Scand Suppl 1986, 707:7-14.
129. Elsner D., Stewart D.J., Sommer O., Holtz J., Bassenge E. Postsynaptic alpha 1- and alpha 2-adrenergic receptors in adrenergic control of capacitance vessel tone in vivo. Hypertension 1986, 8:1003-1014.
130. Auer L.M., Johansson B.B. Pial venous constriction during cervical sympathetic stimulation in the cat. Acta Physiol Scand 1980, 110:203-205.
131. Auer L.M., Johansson B.B. Cervical sympathetic nerve stimulation decreases intracranial pressure in the cat. Acta Physiol Scand 1981, 113:565-566.
132. Wilson T.D., Shoemaker J.K., Kozak R., Lee T.Y., Gelb A.W. Reflex-mediated reduction in human cerebral blood volume. J Cereb Blood Flow Metab 2005, 25:136-143.
133. Zhang R., Zuckerman J.H., Iwasaki K., Wilson T.E., Crandall C.G., Levine B.D. Autonomic neural control of dynamic cerebral autoregulation in humans. Circulation 2002, 106:1814-1820.
134. Ogoh S., Brothers R.M., Eubank W.L., Raven P.B. Autonomic neural control of the cerebral vasculature: acute hypotension. Stroke 2008, 39:1979-1987.
135. Markina L.D., Poboronchuk I.V., Genailo A.N. The cholinergic and adrenergic innervation of the great cerebral vein. Fiziol Zh SSSR Im I M Sechenova 1990, 76:473-479.
136. Nakakita K., Imai H., Kamei I., Naka Y., Nakai K., Itakura T., et al. Innervation of the cerebral veins as compared with the cerebral arteries: a histochemical and electron microscopic study. J Cereb Blood Flow Metab 1983, 3:127-132.
137. Sancesario G., Cavallotti C., Amenta F. The autonomic innervation of rat jugular vein. Cell Tissue Res 1982, 222:691-693.
138. Okamura T., Ayajiki K., Fujioka H., Shinozaki K., Toda N. Neurogenic cerebral vasodilation mediated by nitric oxide. Jpn J Pharmacol 2002, 88:32-38.
139. Glick M.R., Gehman J.D., Gascho J.A. Endothelium-derived nitric oxide reduces baseline venous tone in awake instrumented rats. Am J Physiol 1993, 265:H47-H51.
140. Yuceyar N., Taskiran D., Sagduyu A. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Clin Neurol Neurosurg 2001, 103:206-211.
141. Aydemir M., Yazisiz V., Basarici I., Avci A.B., Erbasan F., Belgi A., et al. Cardiac autonomic profile in rheumatoid arthritis and systemic lupus erythematosus. Lupus 2010, 19:255-261.
142. Ananthakrishnan A.N., Issa M., Barboi A., Jaradeh S., Zadvornova Y., Skaros S., et al. Impact of autonomic dysfunction on inflammatory bowel disease. J Clin Gastroenterol 2010, 44:272-279.
143. Fernandes de Abreu D.A., Eyles D., Feron F. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 2009, 34(Suppl. 1):S265-S277.
144. Gopinath K., Danda D. Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomised controlled trial. Int J Rheum Dis 2011, 14:332-339.
145. Brenner T., Timore Y., Wirguin I., Abramsky O., Steinitz M. In vitro synthesis of antibodies to acetylcholine receptor by Epstein-Barr virus-stimulated B-lymphocytes derived from patients with myasthenia gravis. J Neuroimmunol 1989, 24:217-222.
146. Ebstein R.P., Steinitz M., Mintzer J., Lipshitz I., Stessman J. Beta-adrenergic-stimulated adenylate cyclase activity in normal and EBV-transformed lymphocytes. Experientia 1985, 41:1552-1554.
147. McKendall R.R., Sadiq S.A., Calverley J.R. Unusual manifestations of Epstein-Barr virus encephalomyelitis. Infection 1990, 18:33-35.
148. Stumpf W.E., O'Brien L.P. 1,25 (OH)2 vitamin D3 sites of action in the brain. An autoradiographic study. Histochemistry 1987, 87:393-406.
149. Stumpf W.E., Clark S.A., O'Brien L.P., Reid F.A. 1,25(OH)2 vitamin D3 sites of action in spinal cord and sensory ganglion. Anat Embryol (Berl) 1988, 177:307-310.
150. Santillan G.E., Vazquez G., Boland R.L. Activation of a beta-adrenergic-sensitive signal transduction pathway by the secosteroid hormone 1,25-(OH)2-vitamin D3 in chick heart. J Mol Cell Cardiol 1999, 31:1095-1104.
151. Peeyush Kumar T., Paul J., Antony S., Paulose C.S. Expression of cholinergic, insulin, vitamin D receptors and GLUT 3 in the brainstem of streptozotocin induced diabetic rats: effect of treatment with vitamin D. Neurochem Res 2011, 36:2116-2126.
152. Flachenecker P. Autonomic dysfunction in Guillain-Barre syndrome and multiple sclerosis. J Neurol 2007, 254(Suppl. 2):II96-II101.
153. Sterman A.B., Coyle P.K., Panasci D.J., Grimson R. Disseminated abnormalities of cardiovascular autonomic functions in multiple sclerosis. Neurology 1985, 35:1665-1668.
154. Anema J.R., Heijenbrok M.W., Faes T.J., Heimans J.J., Lanting P., Polman C.H. Cardiovascular autonomic function in multiple sclerosis. J Neurol Sci 1991, 104:129-134.
155. Acevedo A.R., Nava C., Arriada N., Violante A., Corona T. Cardiovascular dysfunction in multiple sclerosis. Acta Neurol Scand 2000, 101:85-88.
156. Bastianello S., Romani A., Viselner G., Tibaldi E.C., Giugni E., Altieri M., et al. Chronic cerebrospinal venous insufficiency in multiple sclerosis: clinical correlates from a multicentre study. BMC Neurol 2011, 11:132.
157. Flachenecker, P., Leussink, V., Frischholz, C., Schoof J., Brechtelsbauer D., Reiners K., Toyka K., Rieckmann P. Cardiovascular autonomic dysfunction in patients with clinically isolated syndrome: a longitudinal study 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) 2009.
158. Baracchini C., Perini P., Calabrese M., Causin F., Rinaldi F., Gallo P. No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Ann Neurol 2011, 69:90-99.
159. Nunez-Alvarez C.A., Cabiedes J. Pathogenic mechanisms of the anti-phospholipid antibodies. Reumatol Clin 2011, 7:72-76.
160. Milovanovic B., Stojanovic L., Milicevik N., Vasic K., Bjelakovic B., Krotin M. Cardiac autonomic dysfunction in patients with systemic lupus, rheumatoid arthritis and sudden death risk. Srp Arh Celok Lek 2010, 138:26-32.
161. Chong J.Y., Rowland L.P., Utiger R.D. Hashimoto encephalopathy: syndrome or myth?. Arch Neurol 2003, 60:164-171.
162. Akgul E., Kutuk U., Ertek S., Cesur M., Cehreli S., Tore H.F., et al. Cardiac autonomic function and global left ventricular performance in autoimmune eauthyroid chronic thyroiditis: is treatment necessary at the euthyroid stage?. Echocardiography 2011, 28:15-21.
163. Sakakibara R., Hattori T., Yasuda K., Yamanishi T. Micturitional disturbance in acute disseminated encephalomyelitis (ADEM). J Auton Nerv Syst 1996, 60:200-205.
164. Iodice V., Low D.A., Vichayanrat E., Mathias C.J. Cardiovascular autonomic dysfunction in MSA and Parkinson's disease: similarities and differences. J Neurol Sci 2011, 310:133-138.
165. Al-Din A.S., Mir R., Davey R., Lily O., Ghaus N. Trigeminal cephalgias and facial pain syndromes associated with autonomic dysfunction. Cephalalgia 2005, 25:605-611.
166. Dionne A., N.M., Hahn A.F. Autonomic nervous symptoms in primary Sjogren's syndrome. Muscle Nerve 2010, 41:202-207.
167. Pandit L. Transverse myelitis spectrum disorders. Neurol India 2009, 57:126-133.
168. Di Franco M., Iannuccelli C., Alessandri C., Paradiso M., Riccieri V., Libri F., et al. Autonomic dysfunction and neuropeptide Y in fibromyalgia. Clin Exp Rheumatol 2009, 27:S75-S78.
169. Mandl T., Granberg V., Apelqvist J., Wollmer P., Manthorpe R., Jacobsson L.T. Autonomic nervous symptoms in primary Sjogren's syndrome. Rheumatology (Oxford) 2008, 47:914-919.
170. Dolic K., Weinstock-Guttman B., Marr K., Valnarov V., Carl E., Hagemeier J., et al. Risk factors for chronic cerebrospinal venous insufficiency (CCSVI) in a large cohort of volunteers. PLoS One 2011, 6:e28062.
171. Lampert R., Bremner J.D., Su S., Miller A., Lee F., Cheema F., et al. Decreased heart rate variability is associated with higher levels of inflammation in middle-aged men. Am Heart J 2008, 156:759. e1-7.
172. Manfrini O., Pizzi C., Viecca M., Bugiardini R. Abnormalities of cardiac autonomic nervous activity correlate with expansive coronary artery remodeling. Atherosclerosis 2008, 197:183-189.
173. Budeus M., Hennersdorf M., Perings C., Strauer B.E. The prediction of atrial fibrillation recurrence after electrical cardioversion with the chemoreflex sensitivity. Z Kardiol 2004, 93:295-299.
174. Alter P., Rupp H., Rominger M.B., Czerny F., Vollrath A., Klose K.J., et al. A new method to assess ventricular wall stress in patients with heart failure and its relation to heart rate variability. Int J Cardiol 2010, 139:301-303.
175. Hypponen E., Boucher B.J., Berry D.J., Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008, 57:298-305.
176. Rasic-Milutinovic Z.R., Milicevic D.R., Milovanovic B.D., Perunicic-Pekovic G.B., Pencic B.D. Do components of metabolic syndrome contribute to cardiac autonomic neuropathy in non-diabetic patients?. Saudi Med J 2010, 31:650-657.
177. Ehlayel M.S., Bener A., Sabbah A. Is high prevalence of vitamin D deficiency evidence for asthma and allergy risks?. Eur Ann Allergy Clin Immunol 2011, 43:81-88.
178. Lewis M.J., Short A.L., Lewis K.E. Autonomic nervous system control of the cardiovascular and respiratory systems in asthma. Respir Med 2006, 100:1688-1705.
179. Kubo N., Kumazawa T. Functional disturbances of the autonomic nerve in nasal hyperreactivity: an up-date review. Acta Otolaryngol Suppl 1993, 500:97-108.
180. Rossato A., Veronese F., Maggioni F., Vedovetto V., Zancan A., Biasiolo M., et al. Autonomic dysfunction and endothelial changes in migraine sufferers. Panminerva Med 2011, 53:13-18.
181. Dobrek L., Friediger J., Furgala A., Thor P.J. Autonomic nervous system activity in IBS patients estimated by heart rate variability (HRV). Przegl Lek 2006, 63:743-747.
182. Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens 1998, 16:1979-1987.
183. Grassi G., Esler M. How to assess sympathetic activity in humans. J Hypertens 1999, 17:719-734.
184. Mitchell D.A., Lambert G., Secher N.H., Raven P.B., van Lieshout J., Esler M.D. Jugular venous overflow of noradrenaline from the brain: a neurochemical indicator of cerebrovascular sympathetic nerve activity in humans. J Physiol 2009, 587:2589-2597.
185. Sternberg Z. Sympathetic nervous system dysfunction in multiple sclerosis, linking neurodegeneration to a reduced response to therapy. Curr Pharm Des 2012, 18:1635-1644.